Human Platelet Lysate Supports Mouse Skeletal Myoblast Growth but Suppresses Cell Fusion on Nanogrooves

2020 ◽  
Vol 3 (6) ◽  
pp. 3594-3604
Author(s):  
Xuelian Tao ◽  
Ping Du ◽  
Li Li ◽  
Jiao Lin ◽  
Yue Shi ◽  
...  
Keyword(s):  
Cell Fusion ◽  
Human Platelet ◽  
Platelet Lysate ◽  
Skeletal Myoblast ◽  
Human Platelet Lysate

scholarly journals Human platelet lysate delivered via an ocular wound chamber for the treatment of corneal epithelial injuries

2021 ◽  
Vol 206 ◽  
pp. 108493
Author(s):  
Gina L. Griffith ◽  
Andrew W. Holt ◽  
Elof Eriksson ◽  
Anthony J. Johnson ◽  
Jennifer S. McDaniel
Keyword(s):  
Human Platelet ◽  
Platelet Lysate ◽  
Corneal Epithelial ◽  
Human Platelet Lysate

scholarly journals Human platelet lysate improves human cord blood derived ECFC survival and vasculogenesis in three dimensional (3D) collagen matrices

2015 ◽  
Vol 101 ◽  
pp. 72-81 ◽  
Author(s):  
Hyojin Kim ◽  
Nutan Prasain ◽  
Sasidhar Vemula ◽  
Michael J. Ferkowicz ◽  
Momoko Yoshimoto ◽  
...  
Keyword(s):  
Cord Blood ◽  
Human Platelet ◽  
Three Dimensional ◽  
Platelet Lysate ◽  
Human Cord Blood ◽  
Collagen Matrices ◽  
Human Platelet Lysate ◽  
3D Collagen

Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?

Biomaterials ◽  
2016 ◽  
Vol 76 ◽  
pp. 371-387 ◽  
Author(s):  
Thierry Burnouf ◽  
Dirk Strunk ◽  
Mickey B.C. Koh ◽  
Katharina Schallmoser
Keyword(s):  
Human Cell ◽  
Gold Standard ◽  
Bovine Serum ◽  
Human Platelet ◽  
Fetal Bovine Serum ◽  
Platelet Lysate ◽  
Human Platelet Lysate ◽  
Fetal Bovine ◽  
Cell Propagation

Evaluation of different cryoprotective solutions in combination with human platelet lysate: an effective alternative cryoprotectant agent for cell therapy

Cytotherapy ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. S190
Author(s):  
C. Rosell-Valle ◽  
M. Martin-Lopez ◽  
M. Montiel ◽  
I. Piudo ◽  
B. Fernandez ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Human Platelet ◽  
Platelet Lysate ◽  
Effective Alternative ◽  
Human Platelet Lysate

Abstract 23: Intracerebral Transplantation of Autologous Bone Marrow Stem Cell (BMSC) for Subacute Ischemic Stroke, Phase 1 Clinical Trial (RAINBOW Trial)

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Masahito Kawabori ◽  
Hideo Shichinohe ◽  
Satoshi Kuroda ◽  
Kiyohiro Houkin
Keyword(s):  
Bone Marrow ◽  
Ischemic Stroke ◽  
Cell Tracking ◽  
Human Platelet ◽  
Phase 1 ◽  
Photon Emission ◽  
Platelet Lysate ◽  
Emission Computed Tomography ◽  
Intracerebral Transplantation ◽  
Human Platelet Lysate

Background: Recent breakthrough in cell therapy is expected to reverse the neurological sequelae of stroke. We investigated the safety and feasibility of intracerebral transplantation of autologous BMSC in the subacute phase of stroke (RAINBOW trial). Several new aspects including cell labeling and tracking, socioecomonic analysis using QALY, and the use of human platelet lysate instead of fetal bovine serum were adopted. (UNIN ID: UMIN000026130) Methods/Design: This is a phase 1, open-label, uncontrolled, dose-response study enrolling adults with severe motor deficits (mRS>3) 14 days after stroke. Approximately 50 mL of the bone marrow is extracted from the iliac bone of each patient 15 days or later from the onset, and BMSCs are cultured with allogeneic human platelet lysate (PL) and are labeled with superparamagnetic iron oxide for cell tracking using MRI. BMSCs are stereotactically administered around the area of infarction approximately 2 months from the ischemic stroke. Each patient will be administered a dose of 20 or 50 million cells. Neurological scoring, MRI for cell tracking, 18 F-fuorodeoxyglucose positron emission tomography, and 123 I-Iomazenil single photon emission computed tomography will be performed throughout 1 year after the administration. Results: All 7 patients have been successfully finished transplantation, and there was no severe adverse event in any of the patient regarding the surgical procedure nor cell quality. Favorable motor recoveries (change in mRS > 1) are seen in 5 of 7 patients, and cell engraftment and migration to ischemic site was also observed. Discussion: This is a first-in-human trial to use labelled BMSC to the patients with subacute ischemic stroke. Intracerebral transplantation of autologous BMSC is safe and well tolerated. Cell migration to the ischemic boundary can clarify the therapeutic mechanisms.

Sign in / Sign up

Export Citation Format

Share Document